Chemotherapy-Induced Nausea and Vomiting (CINV)
4
Pipeline Programs
2
Companies
2
Clinical Trials
2
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
3
Early DiscoveryClinical DevelopmentMarket
On Market (2)
Approved therapies currently available
M&
U
FOCINVEZApproved
fosaprepitant dimeglumine
Unknown Companyintravenous2023
Competitive Landscape
2 companies ranked by most advanced pipeline stage
M&
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Heron TherapeuticsSUSTOL
Merck & Co.Fosaprepitant dimeglumine
Clinical Trials (2)
Total enrollment: 1,015 patients across 2 trials
Safety Study of Repeat Doses of SUSTOL in Adults
Start: Jul 2022Est. completion: Oct 2025
Phase 4Unknown
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)
Start: Sep 2012Est. completion: Nov 20141,015 patients
Phase 3Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space